Search results

  1. 1.
    0570475 - ÚOCHB 2024 RIV CZ cze J - Journal Article
    Španielová, Hana - Brdička, R.
    Onkolytické viry a léčení nádorového bujení.
    [Oncolytic viruses and cancer treatment.]
    Klinická onkologie. Roč. 36, č. 1 (2023), s. 12-27. ISSN 0862-495X
    R&D Projects: GA MŠMT(CZ) EF16_019/0000729
    Institutional support: RVO:61388963
    Keywords : oncolytic virotherapy * immunotherapy * tumor microenvironment * molecular targeted therapy * neoplasms
    OECD category: Virology
    Method of publishing: Open access
    https://doi.org/10.48095/ccko202312
    Permanent Link: https://hdl.handle.net/11104/0341776
     
     
  2. 2.
    0565333 - ÚOCHB 2023 RIV NL eng J - Journal Article
    Markowicz-Piasecka, M. - Darłak, P. - Markiewicz, A. - Sikora, J. - Adla, Santosh Kumar - Bagina, S. - Huttunen, K. M.
    Current approaches to facilitate improved drug delivery to the central nervous system.
    European Journal of Pharmaceutics and Biopharmaceutics. Roč. 181, December (2022), s. 249-262. ISSN 0939-6411. E-ISSN 1873-3441
    Institutional support: RVO:61388963
    Keywords : drug delivery system * blood–brain barrier (BBB) * central nervous system * brain-targeted therapy * nanotechnology
    OECD category: Biochemistry and molecular biology
    Impact factor: 4.9, year: 2022
    Method of publishing: Limited access
    https://doi.org/10.1016/j.ejpb.2022.11.003
    Permanent Link: https://hdl.handle.net/11104/0336882
     
     
  3. 3.
    0554915 - ÚMG 2022 RIV CH eng J - Journal Article
    Klener, P. - Sovilj, D. - Renesova, N. - Anděra, Ladislav
    BH3 Mimetics in Hematologic Malignancies.
    International Journal of Molecular Sciences. Roč. 22, č. 18 (2021), č. článku 10157. E-ISSN 1422-0067
    Institutional support: RVO:68378050
    Keywords : apoptosis * BH3 mimetics * venetoclax * hematologic malignancies * targeted therapy * resistance * biomarkers
    OECD category: Biochemistry and molecular biology
    Impact factor: 6.208, year: 2021
    Method of publishing: Open access
    https://www.mdpi.com/1422-0067/22/18/10157
    Permanent Link: http://hdl.handle.net/11104/0329534
     
     
  4. 4.
    0531791 - ÚVGZ 2021 RIV GB eng J - Journal Article
    Haddad, Y. - Charousova, M. - Životská, H. - Splichal, Z. - Rodrigo, M. A. M. - Michalkova, H. - Křížková, S. - Tesarova, B. - Richtera, L. - Vítek, Petr - Stokowa-Soltys, K. - Hynek, D. - Milosavljevic, V. - Rex, S. - Heger, Z.
    Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells.
    Journal of Nanobiotechnology. Roč. 18, č. 1 (2020), č. článku 95. E-ISSN 1477-3155
    R&D Projects: GA MŠMT(CZ) LM2018123
    Research Infrastructure: CzeCOS III - 90123
    Institutional support: RVO:86652079
    Keywords : web server * secondary structure * protein * growth * recognition * apoferritin * nanocarrier * strategies * apoptosis * dopamine * Homing peptide * Ferritin * Neuroblastoma * Norepinephrine transporter * Targeted therapy
    OECD category: Environmental biotechnology
    Impact factor: 10.435, year: 2020
    Method of publishing: Open access
    https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00654-x
    Permanent Link: http://hdl.handle.net/11104/0310482
     
     
  5. 5.
    0522862 - ÚMG 2020 RIV GB eng J - Journal Article
    Tichá, I. - Hojný, J. - Michálková, R. - Kodet, O. - Krkavcová, E. - Hájková, N. - Nemejcova, K. - Bartu, M. - Jaksa, R. - Dura, M. - Kanwal, Madiha - Martiníková, Andra Stefania - Macůrek, Libor - Zemankova, P. - Kleibl, Z. - Dundr, P.
    A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
    Scientific Reports. Roč. 9, November (2019), č. článku 17050. ISSN 2045-2322. E-ISSN 2045-2322
    R&D Projects: GA MŠMT(CZ) LM2015062
    Institutional support: RVO:68378050
    Keywords : ultraviolet-radiation * recurrent mutations * driver mutations * targeted therapy * p53 * classification * melanogenesis * expression * network * immunotherapy
    OECD category: Oncology
    Impact factor: 3.998, year: 2019
    Method of publishing: Limited access
    https://www.nature.com/articles/s41598-019-53636-x
    Permanent Link: http://hdl.handle.net/11104/0307282
     
     
  6. 6.
    0480368 - ÚEB 2018 RIV GB eng J - Journal Article
    Dvořáková, Marcela - Landa, Přemysl
    Anti-inflammatory activity of natural stilbenoids: A review.
    Pharmacological Research. Roč. 124, OCT (2017), s. 126-145. ISSN 1043-6618. E-ISSN 1096-1186
    R&D Projects: GA ČR(CZ) GA16-07193S
    Institutional support: RVO:61389030
    Keywords : Bioavailability * Encapsulation * Inflammation * Metabolites * Multi-targeted therapy * Natural stilbenes
    OECD category: Biochemistry and molecular biology
    Impact factor: 4.897, year: 2017
    Permanent Link: http://hdl.handle.net/11104/0276150
    FileDownloadSizeCommentaryVersionAccess
    2017_Dvorakova_PHARMACOLOGICAL RESEARCH_126.pdf42.3 MBOtheropen-access
     
     
  7. 7.
    0369686 - ÚMCH 2012 US eng P - Patent Document
    Ulbrich, Karel - Etrych, Tomáš - Říhová, Blanka - Jelínková, Markéta - Kovář, Marek
    pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy.
    Alexandria: United States Patent and Trademark Office, 2011. Owner: Zentiva, k. s. Date of the patent acceptance: 05.04.2011. Patent Number: US7919076
    Institutional research plan: CEZ:AV0Z40500505; CEZ:AV0Z50200510
    Keywords : cancerostatics * polymer cojugates * targeted therapy
    Subject RIV: CC - Organic Chemistry
    http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7919076&OS=7919076&RS=7919076
    Permanent Link: http://hdl.handle.net/11104/0203694
     
     
  8. 8.
    0339530 - ÚMCH 2010 RU rus P - Patent Document
    Ulbrich, Karel - Etrych, Tomáš - Říhová, Blanka - Jelínková, Markéta - Kovář, Marek
    pH-chuvstvitel'nye polimernye kon'jugaty antraciklinovyh kancerostaticheskih aktivnyh agentov dlja terapii napravlennogo dejstvija.
    [pH sensitive polymer conjugates of anthracycline cancerostatic for targeted therapy.]
    Moskva: Euroasijská patentní organizace, 2006. Owner: Zentiva. Date of the patent registration: 12.02.2002. Date of the patent acceptance: 27.10.2006. Patent Number: 007353
    Institutional research plan: CEZ:AV0Z4050913
    Keywords : cancerostatics * polymer cojugates * targeted therapy
    Subject RIV: CD - Macromolecular Chemistry
    Permanent Link: http://hdl.handle.net/11104/0183033
     
     
  9. 9.
    0338868 - ÚMCH 2010 RIV DE eng, ger, fre P - Patent Document
    Ulbrich, Karel - Etrych, Tomáš - Říhová, Blanka - Jelínková, Markéta - Kovář, Marek
    pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy.
    Munich: European Patent Office, 2009. Owner: Zentiva. Date of the patent registration: 20.12.2002. Date of the patent acceptance: 19.08.2009. Patent Number: EP 1 463 529 B1
    R&D Projects: GA AV ČR KSK4055109
    Institutional research plan: CEZ:AV0Z40500505; CEZ:AV0Z50200510
    Keywords : cancerostatics * polymer cojugates * targeted therapy
    Subject RIV: CC - Organic Chemistry
    Permanent Link: http://hdl.handle.net/11104/0182529
     
     
  10. 10.
    0307788 - ÚMCH 2008 RIV CZ cze P - Patent Document
    Etrych, Tomáš - Ulbrich, Karel
    Polymerní konjugáty doxorubicinu s pH-řízeným uvolňováním léčiva a způsob jejich přípravy.
    [Doxorubicin polymeric conjugates with pH-controlled release of a medicament and process of their preparation.]
    Praha: ÚPV, 2008. Owner: Zentiva. Date of the patent registration: 09.08.2006. Date of the patent acceptance: 03.03.2008. 13 s. Patent Number: 299053
    R&D Projects: GA AV ČR KAN200200651
    Institutional research plan: CEZ:AV0Z40500505
    Keywords : polymer conjugates * doxorubicin * targeted therapy
    Subject RIV: CE - Biochemistry
    Permanent Link: http://hdl.handle.net/11104/0160444
     
     

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.